Related Experiment Videos
Systemic and localized scleroderma in children: current and future treatment options
Margalit E Rosenkranz1, Lucila M A Agle, Petros Efthimiou
1Hospital for Special Surgery, Division of Pediatric Rheumatology, New York, New York, USA.
Paediatric Drugs
|April 13, 2006
Summary
Scleroderma, a rare autoimmune disease causing skin hardening, presents in systemic and localized forms. Early intervention is key, though effective disease-modifying therapies remain elusive for both adult and juvenile cases.
Area of Science:
- Rheumatology
- Dermatology
- Pediatrics
Background:
- Scleroderma encompasses rare, complex diseases characterized by skin hardening and sclerosis.
- It presents as systemic sclerosis (diffuse skin/visceral involvement) or localized scleroderma (regional, often in children).
- Juvenile scleroderma forms are critical due to high mortality (systemic) and growth defects (localized).
Purpose of the Study:
- To review the clinical manifestations, pathogenesis, and therapeutic strategies for both systemic and localized scleroderma, with a focus on pediatric cases.
- To highlight the challenges in pediatric scleroderma research, including disease rarity and self-limiting nature.
- To discuss current and emerging treatment interventions for scleroderma.
Main Methods:
- Literature review of scleroderma, focusing on systemic sclerosis and localized scleroderma.
- Analysis of pathogenic pathways, particularly abnormal collagen deposition and fibrosis.
- Examination of therapeutic approaches for systemic sclerosis (antifibrotics, anti-inflammatories, vasodilators) and localized disease (anti-inflammatories, vitamin D analogs, UV irradiation).
Main Results:
- Scleroderma pathogenesis involves abnormal collagen deposition leading to fibrosis in skin and organs.
- Current treatments for systemic sclerosis include antifibrotics, anti-inflammatories, and vasodilators.
- Treatments for localized disease involve anti-inflammatories, vitamin D analogs, and UV irradiation, with limited evidence from adult studies.
Conclusions:
- No single therapy is highly effective or disease-modifying for systemic sclerosis or localized scleroderma.
- Early initiation of current therapeutic strategies is crucial for maximizing clinical benefits.
- Novel interventions like autologous stem cell transplant and cytokine-directed therapies are under investigation.